Modeling Parkinson's disease

esis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-1971. 4. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005;26:565-571. 5. Comi G, Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr Opin Neurol 2005;18:245-252. 6. Fox RJ, Ransohoff RM. New directions in MS therapeutics: vehicles of hope. Trends Immunol 2004;25:632-636. 7. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009;72:1008-1015. 8. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-912. 9. Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-lbind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-471. 10. Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008;21(Suppl 1):S9–S18. 11. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol 2008;7:852-858. 12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452. 13. Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24. 14. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51. 15. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10(Suppl 1):S62–S64. 16. Kita M, Cohen J, Fox R, et al. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis. Neurology 2004;62:A99. 17. Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13:1107-1117. 18. Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532533. 19. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688. 20. Bosma LV, Kragt JJ, Brieva L, et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009;15:715-720. 21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46:907-911. 22. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-1096. 23. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 2002;199:1-15. 24. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry 2005;76:1255-1258. 25. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955. 26. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007;7:239-244. 27. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006;29:518-527. 28. Aktas O, Ullrich O, Infante-Duarte C, et al. Neuronal damage in brain inflammation. Arch Neurol 2007;64:185-189. 29. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis–a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-925. 30. Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71.